Lysophosphatidic acid receptor 4 as a potential drug target for the treatment of type 2 diabetes
| Project/Area Number |
26860169
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
General pharmacology
|
|---|
| Research Institution | Akita University |
|---|
Principal Investigator |
Ohto-N Takayo 秋田大学, 医学(系)研究科(研究院), 助教 (80511378)
|
|---|
| Project Period (FY) |
2014-04-01 – 2016-03-31
|
| Project Status |
Completed (Fiscal Year 2015)
|
| Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2015: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2014: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Keywords | リゾホスファチジン酸 / 生理活性脂質 / LPA4アンタゴニスト / 創薬 / ２型糖尿病 |
|---|
| Outline of Final Research Achievements |
Lysophosphatidic acid receptor 4 (LPA4)-deficient mice are resistant to high-fat diet-induced diabetes. This observation suggests that LPA4 antagonists may provide new therapeutic approaches for type 2 diabetes. Thus, the purpose of this project was to find LPA4 antagonists by screening a chemical library of Drug Discovery Initiative, The University of Tokyo.
I used rat neuroblastoma B103 cells, which lack endogenous responses to LPA, to assess the functions of LPA4. In contrast to the parental B103 cells, LPA4-expressing B103 cells (B103-LPA4) showed Ca2+ influx in response to LPA. By using B103-LPA4 cells, I identified 37 compounds that activate LPA4 predominantly. Furthermore, I examined commercially available two compounds, which were reported to be LPA4 antagonists, and their derivatives. However, no antagonist activities were detected in these compounds.
|
Report
(3 results)
Research Products
(5 results)
